胰腺腺泡细胞癌:一项多机构研究。

Pancreatic acinar cell carcinoma: a multi-institutional study.

作者信息

Matos Jesus M, Schmidt C Max, Turrini Olivier, Agaram Narasimhan P, Niedergethmann Marco, Saeger Hans Detlev, Merchant Nipun, Johnson Cynthia S, Lillemoe Keith D, Grützmann Robert

机构信息

Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.

出版信息

J Gastrointest Surg. 2009 Aug;13(8):1495-502. doi: 10.1007/s11605-009-0938-z. Epub 2009 Jun 3.

Abstract

INTRODUCTION

The presentation and outcome of patients with acinar cell carcinoma (ACC) of the pancreas compared to the more common ductal cell adenocarcinoma (DCA) may be distinct. This study combines the experience with ACC from multiple academic institutions to better understand its natural history and outcomes.

METHODS

This study is a multi-institutional retrospective review of patients with ACC.

RESULTS

Between 1988 and 2008, 17 patients were identified with pathologically confirmed ACC. Median age at presentation was 59 years. Common presenting symptoms were abdominal pain (60%), back pain (50%), and weight loss (45%). Fifteen patients underwent 16 operations: pancreaticoduodenectomy (nine), distal pancreatectomy (four), and exploratory laparotomy (three). Mean tumor size was 5.3 cm. American Joint Commission on Cancer tumor stages were stage I (two), stage II (eight), stage III (four), and stage IV (three). Overall, 1- and 5-year survival rates were 88% and 50%, respectively. In resected cases (13), 1- and 5-year survival rates were 92% and 53%, respectively. Median survival in resected cases was 61 months. This is in contrast to 1,608 patients with ductal cell adenocarcinoma who underwent resection identified from recent literature reports where the average median survival was only 24 months. There was no discernable difference in the outcomes of patients with ACC between United States and Germany patients.

CONCLUSION

Acinar cell carcinoma of the pancreas is rare and appears to have a presentation and outcome distinct from the more common pancreatic DCA. Based upon these data, the outcome of patients with ACC is superior to that of DCA.

摘要

引言

胰腺腺泡细胞癌(ACC)患者的临床表现和预后可能与更常见的导管细胞腺癌(DCA)不同。本研究综合了多个学术机构对ACC的经验,以更好地了解其自然病程和预后。

方法

本研究是对ACC患者的多机构回顾性研究。

结果

1988年至2008年期间,确定了17例经病理证实的ACC患者。就诊时的中位年龄为59岁。常见的临床表现为腹痛(60%)、背痛(50%)和体重减轻(45%)。15例患者接受了16次手术:胰十二指肠切除术(9例)、胰腺远端切除术(4例)和剖腹探查术(3例)。平均肿瘤大小为5.3厘米。美国癌症联合委员会肿瘤分期为I期(2例)、II期(8例)、III期(4例)和IV期(3例)。总体而言,1年和5年生存率分别为88%和50%。在切除病例(13例)中,1年和5年生存率分别为92%和53%。切除病例的中位生存期为61个月。这与最近文献报道中1608例接受切除的导管细胞腺癌患者形成对比,后者的平均中位生存期仅为24个月。美国患者和德国患者的ACC患者预后没有明显差异。

结论

胰腺腺泡细胞癌罕见,其临床表现和预后似乎与更常见的胰腺DCA不同。基于这些数据,ACC患者的预后优于DCA患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索